Qualitative Research Project Exploring Providers' Perceptions of FAP Patients
Dr. Barbara Jung and her hereditary high-risk team at UIC are looking for participants for their study on exploring providers' perceptions of FAP patients.

Per your clinical experience, your participation in this project would be very valuable. Participation would consist of a 20-30-minute recorded phone interview discussing your experience with FAP patients and your perceptions of their cognitive abilities in comparison with other hereditary GI cancer syndrome patients. Specifically, we will discuss FAP patients' executive functioning skills and your opinions regarding how they process information, make decisions, and reach goals in everyday life. In recognition for your time, compensation will be provided in the form of a Visa gift card. If you are interested in learning more about this project or participating, please contact me directly via email or phone to schedule an appointment time. To participate, please contact:

Lauren Gima, B.S.
Genetic Counseling Student
Northwestern University
Laurengima2017@u.northwestern.edu
(310) 490-7745

Juvenile Polyposis Syndrome (JPS) Study (B. Leach, principal investigator)
A diagnosis of juvenile polyposis syndrome (JPS) is established either by expert opinion clinical criteria and/or the presence of a SMAD4 or BMPR1A mutation. Relatively limited data exist about those who present during childhood/adolescents with a clinical diagnosis of JPS, no family history, and no mutation in SMAD4 or BMPR1A. We hypothesize that there are differences in cancer risks between children with at least 5 colorectal juvenile polyps as compared to those with mutations in SMAD4 or BMPR1A. Our aim is to determine the optimal cut point in polyp number for the diagnosis of JPS that distinguishes cancer risk.
Click here for more information and details on how to collaborate in this study.

ATM Mutations and GI Cancers (M. Hall, principal investigator)
We are looking for collaborators who would be willing to share pedigrees of families with germline ATM mutations (likely pathogenic variants also welcome). We are particularly interested in ATM+ probands/pedigrees/families reporting gastric, GE junction, and colorectal cancers.

Please contact Dr. Michael Hall (michael.hall@fccc.edu), Director GI Risk Assessment at Fox Chase Cancer Center if you have families to contribute and would be interested in collaborating on this study.